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ABSTRACT
Severe acute respiratory syndrome corona virus 2 (SARS CoV 2) seems to display an increasing affinity for the nervous 
system. The ongoing pandemic has made evident that  diverse neurological manifestations may occur with COVID 19. 
Headache and dizziness remain the most common symptoms however stroke, seizures, encephalopathy, neuropathy 
and skeletal muscle injury may be seen. An increasing number of patients report initial anosmia and ageusia. 
Tendency for serious illness is believed to be in the elderly or people with a history of diabetes, high blood pressure and 
heart disease. Many patients on immunosuppressive therapies such as multiple sclerosis, myasthenia gravis or 
sarcoidosis are additionally high risk. Angiotensin-converting enzyme 2 (ACE 2) has been identified as the cellular 
receptor for SARS CoV 2 present in both neurons and glial tissue. The pathophysiology of neurotoxicity at best remains 
elusive with dysregulation of homeostasis and pro inflammatory cytokine production causing direct, indirect and post 
infectious neurological complications. Vigilant observation for neurological involvement is important not only to prevent 
spread of this highly contagious disease but also for appropriate, timely management. A directed neurological 
examination limiting exposure of medical personnel to potentially infected patients is mandatory. Appropriate 
constrained investigations should be considered only if there is a likelihood of changing management. Tele neurology 
consultations, whenever possible is the need of the hour. Outcomes of COVID 19 patients with severe illness and 
neurological complications remains grave. Pharmaceutical research needs to change directions to expedite the 
development of a possible vaccine and also accelerate in the quest for newer antiviral agents. 
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R E V I E W  A R T I C L E
History of Corona Viruses:
Coronavirus disease was initially described in 1931, 
with the first coronavirus (HCoV-229E) isolated from 
humans in 1965. Until the outbreak of severe acute 
respiratory syndrome (SARS CoV) in Guangdong, China 
in 2002 only two human coronaviruses (HCoV) were 
known – HCoV-229E and HCoV-OC43. More than 8000 
SARS CoV cases were reported to the World Health 
Organization (WHO) in 2002-03 and it caused 
approximately 800 deaths worldwide with disease 
identification in 29 countries, last case was seen in 
2004. The Middle East respiratory syndrome 
associated coronavirus (MERS-CoV) was the next 
identified coronavirus in 2012 in Saudi Arabia. Larger 
outbreaks have occurred later in South Korea in 2015 
and in Saudi Arabia in 2018.About 2,500 cases have 
been reported as of January 2020 from more than 26 
countries causing approximately 900 deaths in total. 
Viral genome analysis revealed that SARS-CoV belongs 
to Group B and MERS-CoV belongs to Group C beta 
coronavirus, respectively, and both are closely related 
to coronavirus strains found in bats.1
Intermediate mammalian hosts, such as civet cats, 
have been implicated for SARS CoV before its 
adaptation for human transmission, and evidence 
through virus or antibody detection suggests that the 
dromedary camels are likely the host for MERS-CoV.2
SARS-CoV-2 recently identified in Wuhan China in 
December 2019 is a strain of SARS-CoV and it shares 
the same receptor; angiotensin converting enzyme 2 
(ACE2).  It is believed to have zoonotic origins and has 
close genetic similarity to bat coronaviruses.3
Epidemiology of COVID 19 and Burden of disease:
The WHO was informed of 44 cases of pneumonia of 
unknown microbial etiology in Wuhan-Hubei China on 
31 December 2019. Within a few weeks, the virus was 
identified as SARS CoV 2. Most of the patients in the 
outbreak reported a link to the Huanan South China 
Seafood and live animal Market. Rapid spread occurred 
throughout China and within one month several other 
countries, including Italy, the United States and 
Germany. Since then, the outbreak has escalated 
rapidly, with the WHO first declaring this as a public 
health emergency of international concern on 30 
January 2020 and then formally declaring it a 
pandemic on 11 March 2020. Difficulty controlling 
such an aggressive spread resulted partly due to the 
extensive size of Wuhan; Central China’s transportation 
hub, which has a full-time population of more than 9 
million and a transient population of an additional 5.10 
million. In an attempt to reduce virus transmission, on 
January 23, 2020, authorities locked down Wuhan, but 
by that time approximately 5 million persons had 
already left.4 The WHO COVID-19 Situation Report for 
April 21,2020 reports 2.4 million confirmed cases of 
COVID 19 and 162,956 deaths.5   In Pakistan alone at 
the writing of this manuscript the affected number was 
approximately 10,513 with more than 224 mortalities. 
All provinces in Pakistan have been affected with the 
largest numbers from Punjab as per local authorities. 
The incoming numbers have an increasing trend either 
because of improved testing availability or because the 
peak of this pandemic in Pakistan has not been 
reached and the worst is yet to come.
Demographics and Transmission:
As an emerging acute respiratory infectious disease, 
COVID-19 primarily spreads through the respiratory 
tract. Transmission occurs primarily via respiratory 
droplets  within a range of about 1.8 metres (6 ft). 
Indirect contact via contaminated surfaces is another 
possible cause of infection. The virus is inactivated by 
soap, which destabilizes its lipid bilayer. Based on 
current epidemiological investigation, the incubation 
period is 1–14 days, mostly 3–7 days. The pharynx 
reaches peak viral load approximately four days after 
infection and the COVID-19 is contagious during the 
latency period. It is highly transmissible in humans, 
especially in the elderly and people with underlying 
diseases like hypertension, ischemic heart disease and 
diabetes mellitus.  Each infection from the virus is 
expected to result in 1.4 to 3.9 new infections when no 
members of the community are immune and no 
preventive measures are taken. Emerging evidence 
suggests that ambient temperature has no significant 
impact on the transmission of COVID-19; however, 
further research is required on how weather conditions 
influence transmission.6 The median age of patients is 
47–59 years, and 41.9–45.7% of patients are 
females.7
Data from the largest case series in China found that 
87% of confirmed cases were aged 30 to 79 years, 1% 
were aged 9 years or younger, 1% were aged 10 to 19 
years, and 3% were aged 80 years or older. 
Approximately 51% of patients were male and 49% 
were female.8 In the US, older patients (aged ≥65 
years) accounted for 31% of all cases, 45% of 
hospitalizations, 53% of intensive care unit admissions, 
and 80% of deaths, with the highest incidence of 
severe outcomes in patients aged ≥85 years.9 Infection 
in children is reported much less commonly than 
amongst adults. 
Pathophysiology:
SARS CoV2 is an enveloped, positive sense, single 
stranded RNA virus with a diameter of approximately 
60-140 nanometers. The viral envelope consists of a 
lipid bilayer with four structural proteins known as S 
(spike (E (envelope), M (membrane) and N 
(nucleocapsid). Interaction between the spike protein 
and host cell receptor is essential for virulence and 
infectivity.10 Following invasion of the lung epithelium, 
SARS-CoV directly infects T cells and macrophages, 
contributing to lymphopenia with reduced CD4+ and 
CD8+ cell counts and dysregulation of normal adaptive 
immune responses. Excessive production of 
pro-inflammatory cytokines including interleukins (IL-1, 
IL-6, IL-10), and tumor necrosis factor-alpha with 
subsequent downregulation of anti- inflammatory 
cytokines such as interferon gamma  are thought to 
contribute to excessive inflammation and activation of 
pro-apoptotic pathway.11 In some cases, adaptive 
immune responses might become directed against host 
epitopes, resulting in post-infectious autoimmune 
reactions that prolong the inflammatory phase and 
induce tissue destruction even after the virus has been 
cleared.
Mechanisms of Neuronal injury:
Angiotensin-converting enzyme 2 (ACE 2) is the cellular 
receptor for the new SARS-CoV-2 This is present in 
multiple human organs including the brain and glial 
tissue and thus this makes the central nervous system 
a potential target.12 There may be direct infiltration of 
the CNS through the nasal epithelium and entrance 
into the olfactory pathway with the subsequent 
retrograde trans-synaptic spread. Hematogenous 
spread with secondary neurologic manifestations of 
COVID-19 are thought to be the result of widespread 
dysregulation of homeostasis and cytokine production 
with pulmonary, renal, hepatic, and cardiovascular 
injury.13. Besides coronavirus specific antibodies have 
been shown to activate macrophages resulting in their 
migration into the CNS and ultimately cause 
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demyelination. Infection with COVID 19 promotes 
atherosclerosis, inflammation and local thrombosis in 
the presence of systemic inflammation the resultant 
elevation in C reactive protein and D dimer increases 
the risk of acute cerebrovascular disease.14 Molecular 
mimicry between specific viral proteins and proteins 
on peripheral nerves (gangliosides) leads to an 
innocent bystander attack against the myelin or axon, 
the most likely mechanism behind peripheral nerve 
injury. There is no current evidence of direct viral 
invasion with inflammation and degeneration of motor 
neurons and peripheral nerves as seen in some other 
viral infections like poliovirus, West Nile, Herpes 
Zoster, or Cytomegalovirus etc.
Neurological symptoms:
Neurological signs and symptoms fall into three main 
categories; central nervous symptoms (CNS), 
peripheral nervous symptoms (PNS) and skeletal 
muscular symptoms.3 These clinical features may be 
the presenting complaints or as more commonly seen 
arise during the more frequently seen respiratory and 
febrile illness. CNS manifestations most commonly 
seen include dizziness, headache, impaired 
consciousness, acute cerebrovascular disease, 
ataxia, and seizures. PNS manifestations included 
taste impairment, smell impairment and nerve pain. 
Skeletal muscular injury manifestations include 
myalgias. In the largest study to date on 214 patients 
from Wuhan, China, overall, 78 patients (36.4%) had 
neurologic manifestations. 126 patients (58.9%) had 
non severe infection and 88 patients (41.1%) had 
severe infection according to their respiratory status. 
Patients with severe infection were more likely to 
develop neurologic manifestations, especially acute 
cerebrovascular disease [5.7%]; conscious 
disturbance [14.8%] and skeletal muscle injury 
[19.3%].3 Another recent report of 99 COVID-19 
patients in Wuhan also described neurological 
complications with confusion (9%) and headache 
(8%) being most commonly seen.15 Most neurologic 
manifestations occur early in the illness (median 
time, 1-2 days). Of 6 patients with acute 
cerebrovascular disease, 2 arrived at the emergency 
department owing to the sudden onset of hemiplegia 
but without any typical symptoms of fever, cough, 
anorexia, and diarrhea of COVID-19.  Their lung 
lesions were found by an emergent lung CT and were 
diagnosed as having COVID-19 by a positive 
SARS-CoV-2 nucleic acid detection in the later 
stage.3 Loss of smell and taste may precede 
respiratory symptoms and suggest early neurological 
involvement. The American Academy of 
Otolaryngology recently proposed that anosmia, 
hyposmia, and dysgeusia should be added to the list 
of COVID-19 screening symptoms and urged 
precautionary isolation for individuals with these 
symptoms, even in the absence of respiratory 
disease.16
Neurological syndromes:
Isolated new cases of COVID 19 with neurological 
syndromes are emerging every day from all around 
the world. Ischemic strokes have been reported in 5% 
of patients with severe COVID -19 infections and in 
1% of non-severe infections due to the COVID 19 
from recent data considering the patients are  in a pro 
thrombotic state.3 There was also one patient with 
spontaneous intra cerebral hemorrhage and cerebral 
venous sinus thrombosis each in the same study.
Encephalopathy and acute hemorrhagic necrotizing 
encephalopathy have recently been reported with 
COVID19 which are rare complications of influenza 
and other viral infections.17 Myopathies, 
rhabdomyolyis, viral myositis, critical illness myopathy 
are all possibilities with COVID19. In recently 
published studies from China myalgia developed in up 
to 44% of hospitalized patients and elevated creatine 
kinase in up to 33%.18 There is no proven direct 
causality with Guillain Barre Syndrome as seen in 
some other viruses like influenza, H1N1, ZIKA, EBV 
etc. however some new case reports exist.19 
Association with demyelination including Multiple 
sclerosis and Acute disseminated encephalomyelitis 
has been reported in the past.20
COVID-19 and Stroke
Acute strokes presenting in endemic areas in 
emergency department may need to be checked for 
COVID-19. The stroke team evaluating for patient 
should divide to conserve personal protective 
equipment and limit the potential for accidental 
exposure. Patients needing tissue plasminogen 
activator (tPA) during the one-hour infusion may be 
monitored every 15 minutes by a single stroke team 
member situated in the patient’s room. In cases of 
mechanical thrombectomy, groin checks can be done 
by team members entering for other reasons every 4 
hours after the initial monitoring in the intervention 
radiology suite.21  Non-contrast head CTs with 
possible or confirmed COVID-19 should be reserved 
for patients with significant change in neurologic 
examination. Repeat imaging in neurologically stable 
patients who have not received IV tPA or mechanical 
thrombectomy should be avoided. Additional studies 
including MRI, Echocardiogram’s and Doppler’s 
should be considered only if likelihood of changing 
management. Even in patients without COVID-19, the 
effectiveness of routine brain MRI to guide treatment 
selection is uncertain.22
COVID-19 and Seizures 
Metabolic derangements may be common in 
SARS-CoV2 infected patients and these should be 
evaluated for possibly causing seizures. Severely 
affected have compromised renal and hepatic systems 
and appropriate antiseizure medication should be 
carefully selected. Brivaracetam, lacosamide, 
Levetiracetam, Zonisamide is advised with abnormal 
liver tests.23 
COVID19 and Headache
Headache appears to be the most common 
neurological complaint with COVID-19. The putative 
role of ACE2 in the pathophysiology has recently fueled 
concerns regarding the use of non- steroidal 
anti-inflammatory drugs (NSAIDs) such as ibuprofen, 
commonly used for headache. These are known to 
induce up-regulation of ACE2 and, in theory, may 
facilitate infection with COVID-19.24 Sodium valproate 
should be avoided amid to concerns of liver injury.
COVID-19 and GBS
All patients with suspected or diagnosed COVID-19 with 
acute flaccid weakness should be admitted in intensive 
care units. Elective endotracheal intubation should be 
considered when single breath count test < 20, use of 
accessory muscles or paradoxical breathing and neck 
flexion weakness is noted. The generally considered 
CSF analysis for cytological dissociation, maybe 
warranted if it will change therapeutic decision as it 
may be normal in one third to one half in first week of 
symptoms. NCS 1-2 weeks after symptom onset 
should be considered. Intravenous immunoglobulins 
(IVIg) 2g/kg administered over 5 days is the standard of 
care. Plasmapheresis over 5 cycles is an equally 
efficacious alternative. Mild symptoms may not need 
treatment; decision should be weighed against lengthy 
hospital stay.25 The role of high dose IVIg in a recent 
case series published with COVID-19, all of whom were 
successfully treated at the early stage of clinical 
deterioration with the resultant initiation of a 
randomized controlled trial.26 This may lead us to 
rethink the equal efficacy that has been long 
established when treating patients with muscle or nerve 
involvement with plasma exchange versus IVIg. Serial 
PFTs (pulmonary function tests) at least q8h in first 24 
hours. Daily vital sign, urine output, and last bowel 
movement charting should be maintained for 
anticipating autonomic dysfunction. 27
Neuroimaging
Although the full spectrum of neuro-imaging findings in 
COVID 19 is still unknown. The risk of contamination 
remains high. A non-contrast CT Head to exclude acute 
stroke in patients with possible or confirmed COVID 19 
should be reserved for times when actionable 
information is likely to be obtained, or when a 
significant change in the neurological examination is 
seen. A CT angiogram of the head and neck may be 
required in cases of subarachnoid hemorrhage. 
Additional studies including MRI with gadolinium may 
be required in patients with a history of seizures or 
unexplained encephalopathy. In one recently published 
study from Strasbourg, France, between March 3 and 
April 3, 2020 in patients with confirmed COVID 19 with 
encephalopathy. MRI Brain showed leptomeningeal 
enhancement predominately in occipital lobe in eight 
out of 13 patients. Small diffusion abnormalities 
indicating asymptomatic acute ischemic stroke were 
seen in two patients. Bilateral frontotemporal 
hypo-perfusion was noted in all 11 of these patients 
who underwent perfusion imaging.28 Hemorrhagic ring 
enhancing lesions within the bilateral thalami and 
medial temporal lobes on MRI Brain has been 
described in a patient with acute hemorrhagic 
encephalopathy.17 
Cerebrospinal fluid:
A cerebrospinal fluid (CSF) examination may be 
required to exclude possible causes of impaired 
consciousness. All standard tests to exclude CNS 
infections should be done simultaneously despite of 
suspected encephalitis and encephalopathy due to 
COVID-19. Cerebrospinal fluid is usually clear and 
colorless with mild pleocytosis and lymphocytic 
predominance. CSF oligoclonal bands may be present 
with an identical electrophoretic pattern in serum28. 
SARS-CoV-2 nucleocapsid protein genes can be 
detected by using PCR and is recommended in highly 
suspicious cases. In a recent case report with 
meningitis the opening pressure of CSF was increased 
up to 320 mmH2O. The CSF cell count was 12/µ L.  10 
mononuclear and 2 polymorphonuclear cells without 
red blood cells were noted. Although the specific 
SARSCoV-2 RNA was not detected in the 
nasopharyngeal swab of this patient, it was detected in 
CSF.29
Electroencephalogram: 
Electroencephalogram (EEG) may be needed in 
unexplained drowsiness or with uncontrolled seizures. 
Non-convulsive seizures seen in critically ill patients in 
up to 10% .30 24 hour monitoring maybe required in 
appropriate cases, ideally performed with disposable 
EEG leads. Seizures were observed with other types of 
coronavirus infections in up to 6 - 50% of affected 
children.31 The EEG findings although are non-specific 
may show diffuse or bifrontal slowing consistent with 
encephalopathy.28
Nerve conduction studies and electromyography:
Nerve conduction studies (NCS) and 
electromyography (EMG) may be necessary with 
patient acute flaccid paralysis or myositis. Reports of 
GBS in association with COVID-19 have recently been 
seen.32 An over-emphasis on the fact that NCS and 
EMG are within normal limits in the first 1-2 weeks in 
diseases of the muscle and nerves cannot be made. 
Unnecessary procedures should be avoided as the 
machines may serve as fomites.
Laboratory evaluation:
Laboratory findings in patients with COVID -19 include 
high white blood cell counts, lower lymphocyte count, 
and increased C-reactive protein. Severe infection 
has corresponding higher D-dimer levels, increased 
lactate dehydrogenase, alanine aminotransferase, 
and aspartate aminotransferase levels, with elevated 
blood urea nitrogen, creatinine levels and creatine 
kinase (CPK) levels.
Management:
Patient with neurological manifestations and COVID 
19 may require hospitalization with intensive care 
monitoring. Minimal exposure of healthcare and still 
providing the best possible care to patients should be 
the aim. 
Long term neurological complications of SARS 
and other corona viruses:
Delayed neurologic sequelae after 2 weeks of 
respiratory issues have been described following both 
SARS-CoV-1 and MERS-CoV infection, such as 
peripheral neuropathy, myopathy, Bickerstaff 
brainstem encephalitis, and GBS.33,34
Although there is limited data for COVID-19-related 
psychiatric symptoms currently, survivors of 
SARS-CoV were clinically diagnosed with 
post-traumatic stress disorder (54.5%), depression 
(39%), pain disorder (36.4%), panic disorder 
(32.5%), and obsessive compulsive disorder (15.6%) 
at 31 to 50 months post-infection, a dramatic 
increase from their pre-infection prevalence of any 
psychiatric diagnoses of 3%.35 Parkinsonism is a late 
feature of encephalitis lethargica, first described 
following the influenza pandemic of 1918.36 While 
features of Parkinsonism have not been described in 
association with CoV outbreaks, anti-CoV antibodies 
have been identified in CSF of individuals with 
Parkinson’s disease. It is plausible that this could 
contribute to a  delayed neurodegenerative process 
but this  remains to be seen in COVID-19.
Prognosis: 
Neurological manifestations may have a variable 
prognosis. Patients with milder disease or isolated 
symptoms such as anosmia, ageusia, isolated 
headaches or myalgias suggest a relatively better 
outcome. However, those with more severe systemic 
disease and extensive neurological involvement like 
strokes, encephalitis or Guillain Barre syndrome may 
have a graver outcome.
Future directions for research:
Understanding the full spectrum of the neurotropic 
effects of COVID 19 is still in its maiden stages. 
Neurological manifestations until now have depicted 
the entire neuroaxis is prone to disease. 
Pharmaceutical research needs to change directions 
to expedite the development of a possible vaccine 
and also accelerate in the quest for newer antiviral 
agents. More extensive neurological workup or 
autopsies and isolation of SARS CoV 2 from neural 
tissue may help in aiding us to understand the 
mechanism of COVID 19 better. Management 
protocols may need to be revised as we learn more 
about neurological complications every day.
CONCLUSION:
A multi-disciplinary approach is required to control 
this massive challenge faced by humanity. Health 
care providers should keep a close watch for isolated 
neurological symptoms at presentation when 
evaluating patients for COVID 19 to assure both 
appropriate management and control of disease. A 
directed neurological examination limiting exposure of 
medical personnel to potentially infected patients is 
mandatory. Appropriate constrained investigations 
should be considered only if there is a likelihood of 
changing management. Research for new anti-viral 
drugs and the development of a possible vaccine is 
cardinal for the management. Tele neurology 
consultations whenever possible is the need of the 
hour. Outcomes of COVID 19 patients with severe 
illness and neurological complications remains grave
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identified as SARS CoV 2. Most of the patients in the 
outbreak reported a link to the Huanan South China 
Seafood and live animal Market. Rapid spread occurred 
throughout China and within one month several other 
countries, including Italy, the United States and 
Germany. Since then, the outbreak has escalated 
rapidly, with the WHO first declaring this as a public 
health emergency of international concern on 30 
January 2020 and then formally declaring it a 
pandemic on 11 March 2020. Difficulty controlling 
such an aggressive spread resulted partly due to the 
extensive size of Wuhan; Central China’s transportation 
hub, which has a full-time population of more than 9 
million and a transient population of an additional 5.10 
million. In an attempt to reduce virus transmission, on 
January 23, 2020, authorities locked down Wuhan, but 
by that time approximately 5 million persons had 
already left.4 The WHO COVID-19 Situation Report for 
April 21,2020 reports 2.4 million confirmed cases of 
COVID 19 and 162,956 deaths.5   In Pakistan alone at 
the writing of this manuscript the affected number was 
approximately 10,513 with more than 224 mortalities. 
All provinces in Pakistan have been affected with the 
largest numbers from Punjab as per local authorities. 
The incoming numbers have an increasing trend either 
because of improved testing availability or because the 
peak of this pandemic in Pakistan has not been 
reached and the worst is yet to come.
Demographics and Transmission:
As an emerging acute respiratory infectious disease, 
COVID-19 primarily spreads through the respiratory 
tract. Transmission occurs primarily via respiratory 
droplets  within a range of about 1.8 metres (6 ft). 
Indirect contact via contaminated surfaces is another 
possible cause of infection. The virus is inactivated by 
soap, which destabilizes its lipid bilayer. Based on 
current epidemiological investigation, the incubation 
period is 1–14 days, mostly 3–7 days. The pharynx 
reaches peak viral load approximately four days after 
infection and the COVID-19 is contagious during the 
latency period. It is highly transmissible in humans, 
especially in the elderly and people with underlying 
diseases like hypertension, ischemic heart disease and 
diabetes mellitus.  Each infection from the virus is 
expected to result in 1.4 to 3.9 new infections when no 
members of the community are immune and no 
preventive measures are taken. Emerging evidence 
suggests that ambient temperature has no significant 
impact on the transmission of COVID-19; however, 
further research is required on how weather conditions 
influence transmission.6 The median age of patients is 
47–59 years, and 41.9–45.7% of patients are 
females.7
Data from the largest case series in China found that 
87% of confirmed cases were aged 30 to 79 years, 1% 
were aged 9 years or younger, 1% were aged 10 to 19 
years, and 3% were aged 80 years or older. 
Approximately 51% of patients were male and 49% 
were female.8 In the US, older patients (aged ≥65 
years) accounted for 31% of all cases, 45% of 
hospitalizations, 53% of intensive care unit admissions, 
and 80% of deaths, with the highest incidence of 
severe outcomes in patients aged ≥85 years.9 Infection 
in children is reported much less commonly than 
amongst adults. 
Pathophysiology:
SARS CoV2 is an enveloped, positive sense, single 
stranded RNA virus with a diameter of approximately 
60-140 nanometers. The viral envelope consists of a 
lipid bilayer with four structural proteins known as S 
(spike (E (envelope), M (membrane) and N 
(nucleocapsid). Interaction between the spike protein 
and host cell receptor is essential for virulence and 
infectivity.10 Following invasion of the lung epithelium, 
SARS-CoV directly infects T cells and macrophages, 
contributing to lymphopenia with reduced CD4+ and 
CD8+ cell counts and dysregulation of normal adaptive 
immune responses. Excessive production of 
pro-inflammatory cytokines including interleukins (IL-1, 
IL-6, IL-10), and tumor necrosis factor-alpha with 
subsequent downregulation of anti- inflammatory 
cytokines such as interferon gamma  are thought to 
contribute to excessive inflammation and activation of 
pro-apoptotic pathway.11 In some cases, adaptive 
immune responses might become directed against host 
epitopes, resulting in post-infectious autoimmune 
reactions that prolong the inflammatory phase and 
induce tissue destruction even after the virus has been 
cleared.
Mechanisms of Neuronal injury:
Angiotensin-converting enzyme 2 (ACE 2) is the cellular 
receptor for the new SARS-CoV-2 This is present in 
multiple human organs including the brain and glial 
tissue and thus this makes the central nervous system 
a potential target.12 There may be direct infiltration of 
the CNS through the nasal epithelium and entrance 
into the olfactory pathway with the subsequent 
retrograde trans-synaptic spread. Hematogenous 
spread with secondary neurologic manifestations of 
COVID-19 are thought to be the result of widespread 
dysregulation of homeostasis and cytokine production 
with pulmonary, renal, hepatic, and cardiovascular 
injury.13. Besides coronavirus specific antibodies have 
been shown to activate macrophages resulting in their 
migration into the CNS and ultimately cause 
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demyelination. Infection with COVID 19 promotes 
atherosclerosis, inflammation and local thrombosis in 
the presence of systemic inflammation the resultant 
elevation in C reactive protein and D dimer increases 
the risk of acute cerebrovascular disease.14 Molecular 
mimicry between specific viral proteins and proteins 
on peripheral nerves (gangliosides) leads to an 
innocent bystander attack against the myelin or axon, 
the most likely mechanism behind peripheral nerve 
injury. There is no current evidence of direct viral 
invasion with inflammation and degeneration of motor 
neurons and peripheral nerves as seen in some other 
viral infections like poliovirus, West Nile, Herpes 
Zoster, or Cytomegalovirus etc.
Neurological symptoms:
Neurological signs and symptoms fall into three main 
categories; central nervous symptoms (CNS), 
peripheral nervous symptoms (PNS) and skeletal 
muscular symptoms.3 These clinical features may be 
the presenting complaints or as more commonly seen 
arise during the more frequently seen respiratory and 
febrile illness. CNS manifestations most commonly 
seen include dizziness, headache, impaired 
consciousness, acute cerebrovascular disease, 
ataxia, and seizures. PNS manifestations included 
taste impairment, smell impairment and nerve pain. 
Skeletal muscular injury manifestations include 
myalgias. In the largest study to date on 214 patients 
from Wuhan, China, overall, 78 patients (36.4%) had 
neurologic manifestations. 126 patients (58.9%) had 
non severe infection and 88 patients (41.1%) had 
severe infection according to their respiratory status. 
Patients with severe infection were more likely to 
develop neurologic manifestations, especially acute 
cerebrovascular disease [5.7%]; conscious 
disturbance [14.8%] and skeletal muscle injury 
[19.3%].3 Another recent report of 99 COVID-19 
patients in Wuhan also described neurological 
complications with confusion (9%) and headache 
(8%) being most commonly seen.15 Most neurologic 
manifestations occur early in the illness (median 
time, 1-2 days). Of 6 patients with acute 
cerebrovascular disease, 2 arrived at the emergency 
department owing to the sudden onset of hemiplegia 
but without any typical symptoms of fever, cough, 
anorexia, and diarrhea of COVID-19.  Their lung 
lesions were found by an emergent lung CT and were 
diagnosed as having COVID-19 by a positive 
SARS-CoV-2 nucleic acid detection in the later 
stage.3 Loss of smell and taste may precede 
respiratory symptoms and suggest early neurological 
involvement. The American Academy of 
Otolaryngology recently proposed that anosmia, 
hyposmia, and dysgeusia should be added to the list 
of COVID-19 screening symptoms and urged 
precautionary isolation for individuals with these 
symptoms, even in the absence of respiratory 
disease.16
Neurological syndromes:
Isolated new cases of COVID 19 with neurological 
syndromes are emerging every day from all around 
the world. Ischemic strokes have been reported in 5% 
of patients with severe COVID -19 infections and in 
1% of non-severe infections due to the COVID 19 
from recent data considering the patients are  in a pro 
thrombotic state.3 There was also one patient with 
spontaneous intra cerebral hemorrhage and cerebral 
venous sinus thrombosis each in the same study.
Encephalopathy and acute hemorrhagic necrotizing 
encephalopathy have recently been reported with 
COVID19 which are rare complications of influenza 
and other viral infections.17 Myopathies, 
rhabdomyolyis, viral myositis, critical illness myopathy 
are all possibilities with COVID19. In recently 
published studies from China myalgia developed in up 
to 44% of hospitalized patients and elevated creatine 
kinase in up to 33%.18 There is no proven direct 
causality with Guillain Barre Syndrome as seen in 
some other viruses like influenza, H1N1, ZIKA, EBV 
etc. however some new case reports exist.19 
Association with demyelination including Multiple 
sclerosis and Acute disseminated encephalomyelitis 
has been reported in the past.20
COVID-19 and Stroke
Acute strokes presenting in endemic areas in 
emergency department may need to be checked for 
COVID-19. The stroke team evaluating for patient 
should divide to conserve personal protective 
equipment and limit the potential for accidental 
exposure. Patients needing tissue plasminogen 
activator (tPA) during the one-hour infusion may be 
monitored every 15 minutes by a single stroke team 
member situated in the patient’s room. In cases of 
mechanical thrombectomy, groin checks can be done 
by team members entering for other reasons every 4 
hours after the initial monitoring in the intervention 
radiology suite.21  Non-contrast head CTs with 
possible or confirmed COVID-19 should be reserved 
for patients with significant change in neurologic 
examination. Repeat imaging in neurologically stable 
patients who have not received IV tPA or mechanical 
thrombectomy should be avoided. Additional studies 
including MRI, Echocardiogram’s and Doppler’s 
should be considered only if likelihood of changing 
management. Even in patients without COVID-19, the 
effectiveness of routine brain MRI to guide treatment 
selection is uncertain.22
COVID-19 and Seizures 
Metabolic derangements may be common in 
SARS-CoV2 infected patients and these should be 
evaluated for possibly causing seizures. Severely 
affected have compromised renal and hepatic systems 
and appropriate antiseizure medication should be 
carefully selected. Brivaracetam, lacosamide, 
Levetiracetam, Zonisamide is advised with abnormal 
liver tests.23 
COVID19 and Headache
Headache appears to be the most common 
neurological complaint with COVID-19. The putative 
role of ACE2 in the pathophysiology has recently fueled 
concerns regarding the use of non- steroidal 
anti-inflammatory drugs (NSAIDs) such as ibuprofen, 
commonly used for headache. These are known to 
induce up-regulation of ACE2 and, in theory, may 
facilitate infection with COVID-19.24 Sodium valproate 
should be avoided amid to concerns of liver injury.
COVID-19 and GBS
All patients with suspected or diagnosed COVID-19 with 
acute flaccid weakness should be admitted in intensive 
care units. Elective endotracheal intubation should be 
considered when single breath count test < 20, use of 
accessory muscles or paradoxical breathing and neck 
flexion weakness is noted. The generally considered 
CSF analysis for cytological dissociation, maybe 
warranted if it will change therapeutic decision as it 
may be normal in one third to one half in first week of 
symptoms. NCS 1-2 weeks after symptom onset 
should be considered. Intravenous immunoglobulins 
(IVIg) 2g/kg administered over 5 days is the standard of 
care. Plasmapheresis over 5 cycles is an equally 
efficacious alternative. Mild symptoms may not need 
treatment; decision should be weighed against lengthy 
hospital stay.25 The role of high dose IVIg in a recent 
case series published with COVID-19, all of whom were 
successfully treated at the early stage of clinical 
deterioration with the resultant initiation of a 
randomized controlled trial.26 This may lead us to 
rethink the equal efficacy that has been long 
established when treating patients with muscle or nerve 
involvement with plasma exchange versus IVIg. Serial 
PFTs (pulmonary function tests) at least q8h in first 24 
hours. Daily vital sign, urine output, and last bowel 
movement charting should be maintained for 
anticipating autonomic dysfunction. 27
Neuroimaging
Although the full spectrum of neuro-imaging findings in 
COVID 19 is still unknown. The risk of contamination 
remains high. A non-contrast CT Head to exclude acute 
stroke in patients with possible or confirmed COVID 19 
should be reserved for times when actionable 
information is likely to be obtained, or when a 
significant change in the neurological examination is 
seen. A CT angiogram of the head and neck may be 
required in cases of subarachnoid hemorrhage. 
Additional studies including MRI with gadolinium may 
be required in patients with a history of seizures or 
unexplained encephalopathy. In one recently published 
study from Strasbourg, France, between March 3 and 
April 3, 2020 in patients with confirmed COVID 19 with 
encephalopathy. MRI Brain showed leptomeningeal 
enhancement predominately in occipital lobe in eight 
out of 13 patients. Small diffusion abnormalities 
indicating asymptomatic acute ischemic stroke were 
seen in two patients. Bilateral frontotemporal 
hypo-perfusion was noted in all 11 of these patients 
who underwent perfusion imaging.28 Hemorrhagic ring 
enhancing lesions within the bilateral thalami and 
medial temporal lobes on MRI Brain has been 
described in a patient with acute hemorrhagic 
encephalopathy.17 
Cerebrospinal fluid:
A cerebrospinal fluid (CSF) examination may be 
required to exclude possible causes of impaired 
consciousness. All standard tests to exclude CNS 
infections should be done simultaneously despite of 
suspected encephalitis and encephalopathy due to 
COVID-19. Cerebrospinal fluid is usually clear and 
colorless with mild pleocytosis and lymphocytic 
predominance. CSF oligoclonal bands may be present 
with an identical electrophoretic pattern in serum28. 
SARS-CoV-2 nucleocapsid protein genes can be 
detected by using PCR and is recommended in highly 
suspicious cases. In a recent case report with 
meningitis the opening pressure of CSF was increased 
up to 320 mmH2O. The CSF cell count was 12/µ L.  10 
mononuclear and 2 polymorphonuclear cells without 
red blood cells were noted. Although the specific 
SARSCoV-2 RNA was not detected in the 
nasopharyngeal swab of this patient, it was detected in 
CSF.29
Electroencephalogram: 
Electroencephalogram (EEG) may be needed in 
unexplained drowsiness or with uncontrolled seizures. 
Non-convulsive seizures seen in critically ill patients in 
up to 10% .30 24 hour monitoring maybe required in 
appropriate cases, ideally performed with disposable 
EEG leads. Seizures were observed with other types of 
coronavirus infections in up to 6 - 50% of affected 
children.31 The EEG findings although are non-specific 
may show diffuse or bifrontal slowing consistent with 
encephalopathy.28
Nerve conduction studies and electromyography:
Nerve conduction studies (NCS) and 
electromyography (EMG) may be necessary with 
patient acute flaccid paralysis or myositis. Reports of 
GBS in association with COVID-19 have recently been 
seen.32 An over-emphasis on the fact that NCS and 
EMG are within normal limits in the first 1-2 weeks in 
diseases of the muscle and nerves cannot be made. 
Unnecessary procedures should be avoided as the 
machines may serve as fomites.
Laboratory evaluation:
Laboratory findings in patients with COVID -19 include 
high white blood cell counts, lower lymphocyte count, 
and increased C-reactive protein. Severe infection 
has corresponding higher D-dimer levels, increased 
lactate dehydrogenase, alanine aminotransferase, 
and aspartate aminotransferase levels, with elevated 
blood urea nitrogen, creatinine levels and creatine 
kinase (CPK) levels.
Management:
Patient with neurological manifestations and COVID 
19 may require hospitalization with intensive care 
monitoring. Minimal exposure of healthcare and still 
providing the best possible care to patients should be 
the aim. 
Long term neurological complications of SARS 
and other corona viruses:
Delayed neurologic sequelae after 2 weeks of 
respiratory issues have been described following both 
SARS-CoV-1 and MERS-CoV infection, such as 
peripheral neuropathy, myopathy, Bickerstaff 
brainstem encephalitis, and GBS.33,34
Although there is limited data for COVID-19-related 
psychiatric symptoms currently, survivors of 
SARS-CoV were clinically diagnosed with 
post-traumatic stress disorder (54.5%), depression 
(39%), pain disorder (36.4%), panic disorder 
(32.5%), and obsessive compulsive disorder (15.6%) 
at 31 to 50 months post-infection, a dramatic 
increase from their pre-infection prevalence of any 
psychiatric diagnoses of 3%.35 Parkinsonism is a late 
feature of encephalitis lethargica, first described 
following the influenza pandemic of 1918.36 While 
features of Parkinsonism have not been described in 
association with CoV outbreaks, anti-CoV antibodies 
have been identified in CSF of individuals with 
Parkinson’s disease. It is plausible that this could 
contribute to a  delayed neurodegenerative process 
but this  remains to be seen in COVID-19.
Prognosis: 
Neurological manifestations may have a variable 
prognosis. Patients with milder disease or isolated 
symptoms such as anosmia, ageusia, isolated 
headaches or myalgias suggest a relatively better 
outcome. However, those with more severe systemic 
disease and extensive neurological involvement like 
strokes, encephalitis or Guillain Barre syndrome may 
have a graver outcome.
Future directions for research:
Understanding the full spectrum of the neurotropic 
effects of COVID 19 is still in its maiden stages. 
Neurological manifestations until now have depicted 
the entire neuroaxis is prone to disease. 
Pharmaceutical research needs to change directions 
to expedite the development of a possible vaccine 
and also accelerate in the quest for newer antiviral 
agents. More extensive neurological workup or 
autopsies and isolation of SARS CoV 2 from neural 
tissue may help in aiding us to understand the 
mechanism of COVID 19 better. Management 
protocols may need to be revised as we learn more 
about neurological complications every day.
CONCLUSION:
A multi-disciplinary approach is required to control 
this massive challenge faced by humanity. Health 
care providers should keep a close watch for isolated 
neurological symptoms at presentation when 
evaluating patients for COVID 19 to assure both 
appropriate management and control of disease. A 
directed neurological examination limiting exposure of 
medical personnel to potentially infected patients is 
mandatory. Appropriate constrained investigations 
should be considered only if there is a likelihood of 
changing management. Research for new anti-viral 
drugs and the development of a possible vaccine is 
cardinal for the management. Tele neurology 
consultations whenever possible is the need of the 
hour. Outcomes of COVID 19 patients with severe 
illness and neurological complications remains grave
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identified as SARS CoV 2. Most of the patients in the 
outbreak reported a link to the Huanan South China 
Seafood and live animal Market. Rapid spread occurred 
throughout China and within one month several other 
countries, including Italy, the United States and 
Germany. Since then, the outbreak has escalated 
rapidly, with the WHO first declaring this as a public 
health emergency of international concern on 30 
January 2020 and then formally declaring it a 
pandemic on 11 March 2020. Difficulty controlling 
such an aggressive spread resulted partly due to the 
extensive size of Wuhan; Central China’s transportation 
hub, which has a full-time population of more than 9 
million and a transient population of an additional 5.10 
million. In an attempt to reduce virus transmission, on 
January 23, 2020, authorities locked down Wuhan, but 
by that time approximately 5 million persons had 
already left.4 The WHO COVID-19 Situation Report for 
April 21,2020 reports 2.4 million confirmed cases of 
COVID 19 and 162,956 deaths.5   In Pakistan alone at 
the writing of this manuscript the affected number was 
approximately 10,513 with more than 224 mortalities. 
All provinces in Pakistan have been affected with the 
largest numbers from Punjab as per local authorities. 
The incoming numbers have an increasing trend either 
because of improved testing availability or because the 
peak of this pandemic in Pakistan has not been 
reached and the worst is yet to come.
Demographics and Transmission:
As an emerging acute respiratory infectious disease, 
COVID-19 primarily spreads through the respiratory 
tract. Transmission occurs primarily via respiratory 
droplets  within a range of about 1.8 metres (6 ft). 
Indirect contact via contaminated surfaces is another 
possible cause of infection. The virus is inactivated by 
soap, which destabilizes its lipid bilayer. Based on 
current epidemiological investigation, the incubation 
period is 1–14 days, mostly 3–7 days. The pharynx 
reaches peak viral load approximately four days after 
infection and the COVID-19 is contagious during the 
latency period. It is highly transmissible in humans, 
especially in the elderly and people with underlying 
diseases like hypertension, ischemic heart disease and 
diabetes mellitus.  Each infection from the virus is 
expected to result in 1.4 to 3.9 new infections when no 
members of the community are immune and no 
preventive measures are taken. Emerging evidence 
suggests that ambient temperature has no significant 
impact on the transmission of COVID-19; however, 
further research is required on how weather conditions 
influence transmission.6 The median age of patients is 
47–59 years, and 41.9–45.7% of patients are 
females.7
Data from the largest case series in China found that 
87% of confirmed cases were aged 30 to 79 years, 1% 
were aged 9 years or younger, 1% were aged 10 to 19 
years, and 3% were aged 80 years or older. 
Approximately 51% of patients were male and 49% 
were female.8 In the US, older patients (aged ≥65 
years) accounted for 31% of all cases, 45% of 
hospitalizations, 53% of intensive care unit admissions, 
and 80% of deaths, with the highest incidence of 
severe outcomes in patients aged ≥85 years.9 Infection 
in children is reported much less commonly than 
amongst adults. 
Pathophysiology:
SARS CoV2 is an enveloped, positive sense, single 
stranded RNA virus with a diameter of approximately 
60-140 nanometers. The viral envelope consists of a 
lipid bilayer with four structural proteins known as S 
(spike (E (envelope), M (membrane) and N 
(nucleocapsid). Interaction between the spike protein 
and host cell receptor is essential for virulence and 
infectivity.10 Following invasion of the lung epithelium, 
SARS-CoV directly infects T cells and macrophages, 
contributing to lymphopenia with reduced CD4+ and 
CD8+ cell counts and dysregulation of normal adaptive 
immune responses. Excessive production of 
pro-inflammatory cytokines including interleukins (IL-1, 
IL-6, IL-10), and tumor necrosis factor-alpha with 
subsequent downregulation of anti- inflammatory 
cytokines such as interferon gamma  are thought to 
contribute to excessive inflammation and activation of 
pro-apoptotic pathway.11 In some cases, adaptive 
immune responses might become directed against host 
epitopes, resulting in post-infectious autoimmune 
reactions that prolong the inflammatory phase and 
induce tissue destruction even after the virus has been 
cleared.
Mechanisms of Neuronal injury:
Angiotensin-converting enzyme 2 (ACE 2) is the cellular 
receptor for the new SARS-CoV-2 This is present in 
multiple human organs including the brain and glial 
tissue and thus this makes the central nervous system 
a potential target.12 There may be direct infiltration of 
the CNS through the nasal epithelium and entrance 
into the olfactory pathway with the subsequent 
retrograde trans-synaptic spread. Hematogenous 
spread with secondary neurologic manifestations of 
COVID-19 are thought to be the result of widespread 
dysregulation of homeostasis and cytokine production 
with pulmonary, renal, hepatic, and cardiovascular 
injury.13. Besides coronavirus specific antibodies have 
been shown to activate macrophages resulting in their 
migration into the CNS and ultimately cause 
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demyelination. Infection with COVID 19 promotes 
atherosclerosis, inflammation and local thrombosis in 
the presence of systemic inflammation the resultant 
elevation in C reactive protein and D dimer increases 
the risk of acute cerebrovascular disease.14 Molecular 
mimicry between specific viral proteins and proteins 
on peripheral nerves (gangliosides) leads to an 
innocent bystander attack against the myelin or axon, 
the most likely mechanism behind peripheral nerve 
injury. There is no current evidence of direct viral 
invasion with inflammation and degeneration of motor 
neurons and peripheral nerves as seen in some other 
viral infections like poliovirus, West Nile, Herpes 
Zoster, or Cytomegalovirus etc.
Neurological symptoms:
Neurological signs and symptoms fall into three main 
categories; central nervous symptoms (CNS), 
peripheral nervous symptoms (PNS) and skeletal 
muscular symptoms.3 These clinical features may be 
the presenting complaints or as more commonly seen 
arise during the more frequently seen respiratory and 
febrile illness. CNS manifestations most commonly 
seen include dizziness, headache, impaired 
consciousness, acute cerebrovascular disease, 
ataxia, and seizures. PNS manifestations included 
taste impairment, smell impairment and nerve pain. 
Skeletal muscular injury manifestations include 
myalgias. In the largest study to date on 214 patients 
from Wuhan, China, overall, 78 patients (36.4%) had 
neurologic manifestations. 126 patients (58.9%) had 
non severe infection and 88 patients (41.1%) had 
severe infection according to their respiratory status. 
Patients with severe infection were more likely to 
develop neurologic manifestations, especially acute 
cerebrovascular disease [5.7%]; conscious 
disturbance [14.8%] and skeletal muscle injury 
[19.3%].3 Another recent report of 99 COVID-19 
patients in Wuhan also described neurological 
complications with confusion (9%) and headache 
(8%) being most commonly seen.15 Most neurologic 
manifestations occur early in the illness (median 
time, 1-2 days). Of 6 patients with acute 
cerebrovascular disease, 2 arrived at the emergency 
department owing to the sudden onset of hemiplegia 
but without any typical symptoms of fever, cough, 
anorexia, and diarrhea of COVID-19.  Their lung 
lesions were found by an emergent lung CT and were 
diagnosed as having COVID-19 by a positive 
SARS-CoV-2 nucleic acid detection in the later 
stage.3 Loss of smell and taste may precede 
respiratory symptoms and suggest early neurological 
involvement. The American Academy of 
Otolaryngology recently proposed that anosmia, 
hyposmia, and dysgeusia should be added to the list 
of COVID-19 screening symptoms and urged 
precautionary isolation for individuals with these 
symptoms, even in the absence of respiratory 
disease.16
Neurological syndromes:
Isolated new cases of COVID 19 with neurological 
syndromes are emerging every day from all around 
the world. Ischemic strokes have been reported in 5% 
of patients with severe COVID -19 infections and in 
1% of non-severe infections due to the COVID 19 
from recent data considering the patients are  in a pro 
thrombotic state.3 There was also one patient with 
spontaneous intra cerebral hemorrhage and cerebral 
venous sinus thrombosis each in the same study.
Encephalopathy and acute hemorrhagic necrotizing 
encephalopathy have recently been reported with 
COVID19 which are rare complications of influenza 
and other viral infections.17 Myopathies, 
rhabdomyolyis, viral myositis, critical illness myopathy 
are all possibilities with COVID19. In recently 
published studies from China myalgia developed in up 
to 44% of hospitalized patients and elevated creatine 
kinase in up to 33%.18 There is no proven direct 
causality with Guillain Barre Syndrome as seen in 
some other viruses like influenza, H1N1, ZIKA, EBV 
etc. however some new case reports exist.19 
Association with demyelination including Multiple 
sclerosis and Acute disseminated encephalomyelitis 
has been reported in the past.20
COVID-19 and Stroke
Acute strokes presenting in endemic areas in 
emergency department may need to be checked for 
COVID-19. The stroke team evaluating for patient 
should divide to conserve personal protective 
equipment and limit the potential for accidental 
exposure. Patients needing tissue plasminogen 
activator (tPA) during the one-hour infusion may be 
monitored every 15 minutes by a single stroke team 
member situated in the patient’s room. In cases of 
mechanical thrombectomy, groin checks can be done 
by team members entering for other reasons every 4 
hours after the initial monitoring in the intervention 
radiology suite.21  Non-contrast head CTs with 
possible or confirmed COVID-19 should be reserved 
for patients with significant change in neurologic 
examination. Repeat imaging in neurologically stable 
patients who have not received IV tPA or mechanical 
thrombectomy should be avoided. Additional studies 
including MRI, Echocardiogram’s and Doppler’s 
should be considered only if likelihood of changing 
management. Even in patients without COVID-19, the 
effectiveness of routine brain MRI to guide treatment 
selection is uncertain.22
COVID-19 and Seizures 
Metabolic derangements may be common in 
SARS-CoV2 infected patients and these should be 
evaluated for possibly causing seizures. Severely 
affected have compromised renal and hepatic systems 
and appropriate antiseizure medication should be 
carefully selected. Brivaracetam, lacosamide, 
Levetiracetam, Zonisamide is advised with abnormal 
liver tests.23 
COVID19 and Headache
Headache appears to be the most common 
neurological complaint with COVID-19. The putative 
role of ACE2 in the pathophysiology has recently fueled 
concerns regarding the use of non- steroidal 
anti-inflammatory drugs (NSAIDs) such as ibuprofen, 
commonly used for headache. These are known to 
induce up-regulation of ACE2 and, in theory, may 
facilitate infection with COVID-19.24 Sodium valproate 
should be avoided amid to concerns of liver injury.
COVID-19 and GBS
All patients with suspected or diagnosed COVID-19 with 
acute flaccid weakness should be admitted in intensive 
care units. Elective endotracheal intubation should be 
considered when single breath count test < 20, use of 
accessory muscles or paradoxical breathing and neck 
flexion weakness is noted. The generally considered 
CSF analysis for cytological dissociation, maybe 
warranted if it will change therapeutic decision as it 
may be normal in one third to one half in first week of 
symptoms. NCS 1-2 weeks after symptom onset 
should be considered. Intravenous immunoglobulins 
(IVIg) 2g/kg administered over 5 days is the standard of 
care. Plasmapheresis over 5 cycles is an equally 
efficacious alternative. Mild symptoms may not need 
treatment; decision should be weighed against lengthy 
hospital stay.25 The role of high dose IVIg in a recent 
case series published with COVID-19, all of whom were 
successfully treated at the early stage of clinical 
deterioration with the resultant initiation of a 
randomized controlled trial.26 This may lead us to 
rethink the equal efficacy that has been long 
established when treating patients with muscle or nerve 
involvement with plasma exchange versus IVIg. Serial 
PFTs (pulmonary function tests) at least q8h in first 24 
hours. Daily vital sign, urine output, and last bowel 
movement charting should be maintained for 
anticipating autonomic dysfunction. 27
Neuroimaging
Although the full spectrum of neuro-imaging findings in 
COVID 19 is still unknown. The risk of contamination 
remains high. A non-contrast CT Head to exclude acute 
stroke in patients with possible or confirmed COVID 19 
should be reserved for times when actionable 
information is likely to be obtained, or when a 
significant change in the neurological examination is 
seen. A CT angiogram of the head and neck may be 
required in cases of subarachnoid hemorrhage. 
Additional studies including MRI with gadolinium may 
be required in patients with a history of seizures or 
unexplained encephalopathy. In one recently published 
study from Strasbourg, France, between March 3 and 
April 3, 2020 in patients with confirmed COVID 19 with 
encephalopathy. MRI Brain showed leptomeningeal 
enhancement predominately in occipital lobe in eight 
out of 13 patients. Small diffusion abnormalities 
indicating asymptomatic acute ischemic stroke were 
seen in two patients. Bilateral frontotemporal 
hypo-perfusion was noted in all 11 of these patients 
who underwent perfusion imaging.28 Hemorrhagic ring 
enhancing lesions within the bilateral thalami and 
medial temporal lobes on MRI Brain has been 
described in a patient with acute hemorrhagic 
encephalopathy.17 
Cerebrospinal fluid:
A cerebrospinal fluid (CSF) examination may be 
required to exclude possible causes of impaired 
consciousness. All standard tests to exclude CNS 
infections should be done simultaneously despite of 
suspected encephalitis and encephalopathy due to 
COVID-19. Cerebrospinal fluid is usually clear and 
colorless with mild pleocytosis and lymphocytic 
predominance. CSF oligoclonal bands may be present 
with an identical electrophoretic pattern in serum28. 
SARS-CoV-2 nucleocapsid protein genes can be 
detected by using PCR and is recommended in highly 
suspicious cases. In a recent case report with 
meningitis the opening pressure of CSF was increased 
up to 320 mmH2O. The CSF cell count was 12/µ L.  10 
mononuclear and 2 polymorphonuclear cells without 
red blood cells were noted. Although the specific 
SARSCoV-2 RNA was not detected in the 
nasopharyngeal swab of this patient, it was detected in 
CSF.29
Electroencephalogram: 
Electroencephalogram (EEG) may be needed in 
unexplained drowsiness or with uncontrolled seizures. 
Non-convulsive seizures seen in critically ill patients in 
up to 10% .30 24 hour monitoring maybe required in 
appropriate cases, ideally performed with disposable 
EEG leads. Seizures were observed with other types of 
coronavirus infections in up to 6 - 50% of affected 
children.31 The EEG findings although are non-specific 
may show diffuse or bifrontal slowing consistent with 
encephalopathy.28
Nerve conduction studies and electromyography:
Nerve conduction studies (NCS) and 
electromyography (EMG) may be necessary with 
patient acute flaccid paralysis or myositis. Reports of 
GBS in association with COVID-19 have recently been 
seen.32 An over-emphasis on the fact that NCS and 
EMG are within normal limits in the first 1-2 weeks in 
diseases of the muscle and nerves cannot be made. 
Unnecessary procedures should be avoided as the 
machines may serve as fomites.
Laboratory evaluation:
Laboratory findings in patients with COVID -19 include 
high white blood cell counts, lower lymphocyte count, 
and increased C-reactive protein. Severe infection 
has corresponding higher D-dimer levels, increased 
lactate dehydrogenase, alanine aminotransferase, 
and aspartate aminotransferase levels, with elevated 
blood urea nitrogen, creatinine levels and creatine 
kinase (CPK) levels.
Management:
Patient with neurological manifestations and COVID 
19 may require hospitalization with intensive care 
monitoring. Minimal exposure of healthcare and still 
providing the best possible care to patients should be 
the aim. 
Long term neurological complications of SARS 
and other corona viruses:
Delayed neurologic sequelae after 2 weeks of 
respiratory issues have been described following both 
SARS-CoV-1 and MERS-CoV infection, such as 
peripheral neuropathy, myopathy, Bickerstaff 
brainstem encephalitis, and GBS.33,34
Although there is limited data for COVID-19-related 
psychiatric symptoms currently, survivors of 
SARS-CoV were clinically diagnosed with 
post-traumatic stress disorder (54.5%), depression 
(39%), pain disorder (36.4%), panic disorder 
(32.5%), and obsessive compulsive disorder (15.6%) 
at 31 to 50 months post-infection, a dramatic 
increase from their pre-infection prevalence of any 
psychiatric diagnoses of 3%.35 Parkinsonism is a late 
feature of encephalitis lethargica, first described 
following the influenza pandemic of 1918.36 While 
features of Parkinsonism have not been described in 
association with CoV outbreaks, anti-CoV antibodies 
have been identified in CSF of individuals with 
Parkinson’s disease. It is plausible that this could 
contribute to a  delayed neurodegenerative process 
but this  remains to be seen in COVID-19.
Prognosis: 
Neurological manifestations may have a variable 
prognosis. Patients with milder disease or isolated 
symptoms such as anosmia, ageusia, isolated 
headaches or myalgias suggest a relatively better 
outcome. However, those with more severe systemic 
disease and extensive neurological involvement like 
strokes, encephalitis or Guillain Barre syndrome may 
have a graver outcome.
Future directions for research:
Understanding the full spectrum of the neurotropic 
effects of COVID 19 is still in its maiden stages. 
Neurological manifestations until now have depicted 
the entire neuroaxis is prone to disease. 
Pharmaceutical research needs to change directions 
to expedite the development of a possible vaccine 
and also accelerate in the quest for newer antiviral 
agents. More extensive neurological workup or 
autopsies and isolation of SARS CoV 2 from neural 
tissue may help in aiding us to understand the 
mechanism of COVID 19 better. Management 
protocols may need to be revised as we learn more 
about neurological complications every day.
CONCLUSION:
A multi-disciplinary approach is required to control 
this massive challenge faced by humanity. Health 
care providers should keep a close watch for isolated 
neurological symptoms at presentation when 
evaluating patients for COVID 19 to assure both 
appropriate management and control of disease. A 
directed neurological examination limiting exposure of 
medical personnel to potentially infected patients is 
mandatory. Appropriate constrained investigations 
should be considered only if there is a likelihood of 
changing management. Research for new anti-viral 
drugs and the development of a possible vaccine is 
cardinal for the management. Tele neurology 
consultations whenever possible is the need of the 
hour. Outcomes of COVID 19 patients with severe 
illness and neurological complications remains grave
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identified as SARS CoV 2. Most of the patients in the 
outbreak reported a link to the Huanan South China 
Seafood and live animal Market. Rapid spread occurred 
throughout China and within one month several other 
countries, including Italy, the United States and 
Germany. Since then, the outbreak has escalated 
rapidly, with the WHO first declaring this as a public 
health emergency of international concern on 30 
January 2020 and then formally declaring it a 
pandemic on 11 March 2020. Difficulty controlling 
such an aggressive spread resulted partly due to the 
extensive size of Wuhan; Central China’s transportation 
hub, which has a full-time population of more than 9 
million and a transient population of an additional 5.10 
million. In an attempt to reduce virus transmission, on 
January 23, 2020, authorities locked down Wuhan, but 
by that time approximately 5 million persons had 
already left.4 The WHO COVID-19 Situation Report for 
April 21,2020 reports 2.4 million confirmed cases of 
COVID 19 and 162,956 deaths.5   In Pakistan alone at 
the writing of this manuscript the affected number was 
approximately 10,513 with more than 224 mortalities. 
All provinces in Pakistan have been affected with the 
largest numbers from Punjab as per local authorities. 
The incoming numbers have an increasing trend either 
because of improved testing availability or because the 
peak of this pandemic in Pakistan has not been 
reached and the worst is yet to come.
Demographics and Transmission:
As an emerging acute respiratory infectious disease, 
COVID-19 primarily spreads through the respiratory 
tract. Transmission occurs primarily via respiratory 
droplets  within a range of about 1.8 metres (6 ft). 
Indirect contact via contaminated surfaces is another 
possible cause of infection. The virus is inactivated by 
soap, which destabilizes its lipid bilayer. Based on 
current epidemiological investigation, the incubation 
period is 1–14 days, mostly 3–7 days. The pharynx 
reaches peak viral load approximately four days after 
infection and the COVID-19 is contagious during the 
latency period. It is highly transmissible in humans, 
especially in the elderly and people with underlying 
diseases like hypertension, ischemic heart disease and 
diabetes mellitus.  Each infection from the virus is 
expected to result in 1.4 to 3.9 new infections when no 
members of the community are immune and no 
preventive measures are taken. Emerging evidence 
suggests that ambient temperature has no significant 
impact on the transmission of COVID-19; however, 
further research is required on how weather conditions 
influence transmission.6 The median age of patients is 
47–59 years, and 41.9–45.7% of patients are 
females.7
Data from the largest case series in China found that 
87% of confirmed cases were aged 30 to 79 years, 1% 
were aged 9 years or younger, 1% were aged 10 to 19 
years, and 3% were aged 80 years or older. 
Approximately 51% of patients were male and 49% 
were female.8 In the US, older patients (aged ≥65 
years) accounted for 31% of all cases, 45% of 
hospitalizations, 53% of intensive care unit admissions, 
and 80% of deaths, with the highest incidence of 
severe outcomes in patients aged ≥85 years.9 Infection 
in children is reported much less commonly than 
amongst adults. 
Pathophysiology:
SARS CoV2 is an enveloped, positive sense, single 
stranded RNA virus with a diameter of approximately 
60-140 nanometers. The viral envelope consists of a 
lipid bilayer with four structural proteins known as S 
(spike (E (envelope), M (membrane) and N 
(nucleocapsid). Interaction between the spike protein 
and host cell receptor is essential for virulence and 
infectivity.10 Following invasion of the lung epithelium, 
SARS-CoV directly infects T cells and macrophages, 
contributing to lymphopenia with reduced CD4+ and 
CD8+ cell counts and dysregulation of normal adaptive 
immune responses. Excessive production of 
pro-inflammatory cytokines including interleukins (IL-1, 
IL-6, IL-10), and tumor necrosis factor-alpha with 
subsequent downregulation of anti- inflammatory 
cytokines such as interferon gamma  are thought to 
contribute to excessive inflammation and activation of 
pro-apoptotic pathway.11 In some cases, adaptive 
immune responses might become directed against host 
epitopes, resulting in post-infectious autoimmune 
reactions that prolong the inflammatory phase and 
induce tissue destruction even after the virus has been 
cleared.
Mechanisms of Neuronal injury:
Angiotensin-converting enzyme 2 (ACE 2) is the cellular 
receptor for the new SARS-CoV-2 This is present in 
multiple human organs including the brain and glial 
tissue and thus this makes the central nervous system 
a potential target.12 There may be direct infiltration of 
the CNS through the nasal epithelium and entrance 
into the olfactory pathway with the subsequent 
retrograde trans-synaptic spread. Hematogenous 
spread with secondary neurologic manifestations of 
COVID-19 are thought to be the result of widespread 
dysregulation of homeostasis and cytokine production 
with pulmonary, renal, hepatic, and cardiovascular 
injury.13. Besides coronavirus specific antibodies have 
been shown to activate macrophages resulting in their 
migration into the CNS and ultimately cause 
demyelination. Infection with COVID 19 promotes 
atherosclerosis, inflammation and local thrombosis in 
the presence of systemic inflammation the resultant 
elevation in C reactive protein and D dimer increases 
the risk of acute cerebrovascular disease.14 Molecular 
mimicry between specific viral proteins and proteins 
on peripheral nerves (gangliosides) leads to an 
innocent bystander attack against the myelin or axon, 
the most likely mechanism behind peripheral nerve 
injury. There is no current evidence of direct viral 
invasion with inflammation and degeneration of motor 
neurons and peripheral nerves as seen in some other 
viral infections like poliovirus, West Nile, Herpes 
Zoster, or Cytomegalovirus etc.
Neurological symptoms:
Neurological signs and symptoms fall into three main 
categories; central nervous symptoms (CNS), 
peripheral nervous symptoms (PNS) and skeletal 
muscular symptoms.3 These clinical features may be 
the presenting complaints or as more commonly seen 
arise during the more frequently seen respiratory and 
febrile illness. CNS manifestations most commonly 
seen include dizziness, headache, impaired 
consciousness, acute cerebrovascular disease, 
ataxia, and seizures. PNS manifestations included 
taste impairment, smell impairment and nerve pain. 
Skeletal muscular injury manifestations include 
myalgias. In the largest study to date on 214 patients 
from Wuhan, China, overall, 78 patients (36.4%) had 
neurologic manifestations. 126 patients (58.9%) had 
non severe infection and 88 patients (41.1%) had 
severe infection according to their respiratory status. 
Patients with severe infection were more likely to 
develop neurologic manifestations, especially acute 
cerebrovascular disease [5.7%]; conscious 
disturbance [14.8%] and skeletal muscle injury 
[19.3%].3 Another recent report of 99 COVID-19 
patients in Wuhan also described neurological 
complications with confusion (9%) and headache 
(8%) being most commonly seen.15 Most neurologic 
manifestations occur early in the illness (median 
time, 1-2 days). Of 6 patients with acute 
cerebrovascular disease, 2 arrived at the emergency 
department owing to the sudden onset of hemiplegia 
but without any typical symptoms of fever, cough, 
anorexia, and diarrhea of COVID-19.  Their lung 
lesions were found by an emergent lung CT and were 
diagnosed as having COVID-19 by a positive 
SARS-CoV-2 nucleic acid detection in the later 
stage.3 Loss of smell and taste may precede 
respiratory symptoms and suggest early neurological 
involvement. The American Academy of 
Otolaryngology recently proposed that anosmia, 
hyposmia, and dysgeusia should be added to the list 
of COVID-19 screening symptoms and urged 
precautionary isolation for individuals with these 
symptoms, even in the absence of respiratory 
disease.16
Neurological syndromes:
Isolated new cases of COVID 19 with neurological 
syndromes are emerging every day from all around 
the world. Ischemic strokes have been reported in 5% 
of patients with severe COVID -19 infections and in 
1% of non-severe infections due to the COVID 19 
from recent data considering the patients are  in a pro 
thrombotic state.3 There was also one patient with 
spontaneous intra cerebral hemorrhage and cerebral 
venous sinus thrombosis each in the same study.
Encephalopathy and acute hemorrhagic necrotizing 
encephalopathy have recently been reported with 
COVID19 which are rare complications of influenza 
and other viral infections.17 Myopathies, 
rhabdomyolyis, viral myositis, critical illness myopathy 
are all possibilities with COVID19. In recently 
published studies from China myalgia developed in up 
to 44% of hospitalized patients and elevated creatine 
kinase in up to 33%.18 There is no proven direct 
causality with Guillain Barre Syndrome as seen in 
some other viruses like influenza, H1N1, ZIKA, EBV 
etc. however some new case reports exist.19 
Association with demyelination including Multiple 
sclerosis and Acute disseminated encephalomyelitis 
has been reported in the past.20
COVID-19 and Stroke
Acute strokes presenting in endemic areas in 
emergency department may need to be checked for 
COVID-19. The stroke team evaluating for patient 
should divide to conserve personal protective 
equipment and limit the potential for accidental 
exposure. Patients needing tissue plasminogen 
activator (tPA) during the one-hour infusion may be 
monitored every 15 minutes by a single stroke team 
member situated in the patient’s room. In cases of 
mechanical thrombectomy, groin checks can be done 
by team members entering for other reasons every 4 
hours after the initial monitoring in the intervention 
radiology suite.21  Non-contrast head CTs with 
possible or confirmed COVID-19 should be reserved 
for patients with significant change in neurologic 
examination. Repeat imaging in neurologically stable 
patients who have not received IV tPA or mechanical 
thrombectomy should be avoided. Additional studies 
including MRI, Echocardiogram’s and Doppler’s 
should be considered only if likelihood of changing 
management. Even in patients without COVID-19, the 
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effectiveness of routine brain MRI to guide treatment 
selection is uncertain.22
COVID-19 and Seizures 
Metabolic derangements may be common in 
SARS-CoV2 infected patients and these should be 
evaluated for possibly causing seizures. Severely 
affected have compromised renal and hepatic systems 
and appropriate antiseizure medication should be 
carefully selected. Brivaracetam, lacosamide, 
Levetiracetam, Zonisamide is advised with abnormal 
liver tests.23 
COVID19 and Headache
Headache appears to be the most common 
neurological complaint with COVID-19. The putative 
role of ACE2 in the pathophysiology has recently fueled 
concerns regarding the use of non- steroidal 
anti-inflammatory drugs (NSAIDs) such as ibuprofen, 
commonly used for headache. These are known to 
induce up-regulation of ACE2 and, in theory, may 
facilitate infection with COVID-19.24 Sodium valproate 
should be avoided amid to concerns of liver injury.
COVID-19 and GBS
All patients with suspected or diagnosed COVID-19 with 
acute flaccid weakness should be admitted in intensive 
care units. Elective endotracheal intubation should be 
considered when single breath count test < 20, use of 
accessory muscles or paradoxical breathing and neck 
flexion weakness is noted. The generally considered 
CSF analysis for cytological dissociation, maybe 
warranted if it will change therapeutic decision as it 
may be normal in one third to one half in first week of 
symptoms. NCS 1-2 weeks after symptom onset 
should be considered. Intravenous immunoglobulins 
(IVIg) 2g/kg administered over 5 days is the standard of 
care. Plasmapheresis over 5 cycles is an equally 
efficacious alternative. Mild symptoms may not need 
treatment; decision should be weighed against lengthy 
hospital stay.25 The role of high dose IVIg in a recent 
case series published with COVID-19, all of whom were 
successfully treated at the early stage of clinical 
deterioration with the resultant initiation of a 
randomized controlled trial.26 This may lead us to 
rethink the equal efficacy that has been long 
established when treating patients with muscle or nerve 
involvement with plasma exchange versus IVIg. Serial 
PFTs (pulmonary function tests) at least q8h in first 24 
hours. Daily vital sign, urine output, and last bowel 
movement charting should be maintained for 
anticipating autonomic dysfunction. 27
Neuroimaging
Although the full spectrum of neuro-imaging findings in 
COVID 19 is still unknown. The risk of contamination 
remains high. A non-contrast CT Head to exclude acute 
stroke in patients with possible or confirmed COVID 19 
should be reserved for times when actionable 
information is likely to be obtained, or when a 
significant change in the neurological examination is 
seen. A CT angiogram of the head and neck may be 
required in cases of subarachnoid hemorrhage. 
Additional studies including MRI with gadolinium may 
be required in patients with a history of seizures or 
unexplained encephalopathy. In one recently published 
study from Strasbourg, France, between March 3 and 
April 3, 2020 in patients with confirmed COVID 19 with 
encephalopathy. MRI Brain showed leptomeningeal 
enhancement predominately in occipital lobe in eight 
out of 13 patients. Small diffusion abnormalities 
indicating asymptomatic acute ischemic stroke were 
seen in two patients. Bilateral frontotemporal 
hypo-perfusion was noted in all 11 of these patients 
who underwent perfusion imaging.28 Hemorrhagic ring 
enhancing lesions within the bilateral thalami and 
medial temporal lobes on MRI Brain has been 
described in a patient with acute hemorrhagic 
encephalopathy.17 
Cerebrospinal fluid:
A cerebrospinal fluid (CSF) examination may be 
required to exclude possible causes of impaired 
consciousness. All standard tests to exclude CNS 
infections should be done simultaneously despite of 
suspected encephalitis and encephalopathy due to 
COVID-19. Cerebrospinal fluid is usually clear and 
colorless with mild pleocytosis and lymphocytic 
predominance. CSF oligoclonal bands may be present 
with an identical electrophoretic pattern in serum28. 
SARS-CoV-2 nucleocapsid protein genes can be 
detected by using PCR and is recommended in highly 
suspicious cases. In a recent case report with 
meningitis the opening pressure of CSF was increased 
up to 320 mmH2O. The CSF cell count was 12/µ L.  10 
mononuclear and 2 polymorphonuclear cells without 
red blood cells were noted. Although the specific 
SARSCoV-2 RNA was not detected in the 
nasopharyngeal swab of this patient, it was detected in 
CSF.29
Electroencephalogram: 
Electroencephalogram (EEG) may be needed in 
unexplained drowsiness or with uncontrolled seizures. 
Non-convulsive seizures seen in critically ill patients in 
up to 10% .30 24 hour monitoring maybe required in 
appropriate cases, ideally performed with disposable 
EEG leads. Seizures were observed with other types of 
coronavirus infections in up to 6 - 50% of affected 
children.31 The EEG findings although are non-specific 
may show diffuse or bifrontal slowing consistent with 
encephalopathy.28
Nerve conduction studies and electromyography:
Nerve conduction studies (NCS) and 
electromyography (EMG) may be necessary with 
patient acute flaccid paralysis or myositis. Reports of 
GBS in association with COVID-19 have recently been 
seen.32 An over-emphasis on the fact that NCS and 
EMG are within normal limits in the first 1-2 weeks in 
diseases of the muscle and nerves cannot be made. 
Unnecessary procedures should be avoided as the 
machines may serve as fomites.
Laboratory evaluation:
Laboratory findings in patients with COVID -19 include 
high white blood cell counts, lower lymphocyte count, 
and increased C-reactive protein. Severe infection 
has corresponding higher D-dimer levels, increased 
lactate dehydrogenase, alanine aminotransferase, 
and aspartate aminotransferase levels, with elevated 
blood urea nitrogen, creatinine levels and creatine 
kinase (CPK) levels.
Management:
Patient with neurological manifestations and COVID 
19 may require hospitalization with intensive care 
monitoring. Minimal exposure of healthcare and still 
providing the best possible care to patients should be 
the aim. 
Long term neurological complications of SARS 
and other corona viruses:
Delayed neurologic sequelae after 2 weeks of 
respiratory issues have been described following both 
SARS-CoV-1 and MERS-CoV infection, such as 
peripheral neuropathy, myopathy, Bickerstaff 
brainstem encephalitis, and GBS.33,34
Although there is limited data for COVID-19-related 
psychiatric symptoms currently, survivors of 
SARS-CoV were clinically diagnosed with 
post-traumatic stress disorder (54.5%), depression 
(39%), pain disorder (36.4%), panic disorder 
(32.5%), and obsessive compulsive disorder (15.6%) 
at 31 to 50 months post-infection, a dramatic 
increase from their pre-infection prevalence of any 
psychiatric diagnoses of 3%.35 Parkinsonism is a late 
feature of encephalitis lethargica, first described 
following the influenza pandemic of 1918.36 While 
features of Parkinsonism have not been described in 
association with CoV outbreaks, anti-CoV antibodies 
have been identified in CSF of individuals with 
Parkinson’s disease. It is plausible that this could 
contribute to a  delayed neurodegenerative process 
but this  remains to be seen in COVID-19.
Prognosis: 
Neurological manifestations may have a variable 
prognosis. Patients with milder disease or isolated 
symptoms such as anosmia, ageusia, isolated 
headaches or myalgias suggest a relatively better 
outcome. However, those with more severe systemic 
disease and extensive neurological involvement like 
strokes, encephalitis or Guillain Barre syndrome may 
have a graver outcome.
Future directions for research:
Understanding the full spectrum of the neurotropic 
effects of COVID 19 is still in its maiden stages. 
Neurological manifestations until now have depicted 
the entire neuroaxis is prone to disease. 
Pharmaceutical research needs to change directions 
to expedite the development of a possible vaccine 
and also accelerate in the quest for newer antiviral 
agents. More extensive neurological workup or 
autopsies and isolation of SARS CoV 2 from neural 
tissue may help in aiding us to understand the 
mechanism of COVID 19 better. Management 
protocols may need to be revised as we learn more 
about neurological complications every day.
CONCLUSION:
A multi-disciplinary approach is required to control 
this massive challenge faced by humanity. Health 
care providers should keep a close watch for isolated 
neurological symptoms at presentation when 
evaluating patients for COVID 19 to assure both 
appropriate management and control of disease. A 
directed neurological examination limiting exposure of 
medical personnel to potentially infected patients is 
mandatory. Appropriate constrained investigations 
should be considered only if there is a likelihood of 
changing management. Research for new anti-viral 
drugs and the development of a possible vaccine is 
cardinal for the management. Tele neurology 
consultations whenever possible is the need of the 
hour. Outcomes of COVID 19 patients with severe 
illness and neurological complications remains grave
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identified as SARS CoV 2. Most of the patients in the 
outbreak reported a link to the Huanan South China 
Seafood and live animal Market. Rapid spread occurred 
throughout China and within one month several other 
countries, including Italy, the United States and 
Germany. Since then, the outbreak has escalated 
rapidly, with the WHO first declaring this as a public 
health emergency of international concern on 30 
January 2020 and then formally declaring it a 
pandemic on 11 March 2020. Difficulty controlling 
such an aggressive spread resulted partly due to the 
extensive size of Wuhan; Central China’s transportation 
hub, which has a full-time population of more than 9 
million and a transient population of an additional 5.10 
million. In an attempt to reduce virus transmission, on 
January 23, 2020, authorities locked down Wuhan, but 
by that time approximately 5 million persons had 
already left.4 The WHO COVID-19 Situation Report for 
April 21,2020 reports 2.4 million confirmed cases of 
COVID 19 and 162,956 deaths.5   In Pakistan alone at 
the writing of this manuscript the affected number was 
approximately 10,513 with more than 224 mortalities. 
All provinces in Pakistan have been affected with the 
largest numbers from Punjab as per local authorities. 
The incoming numbers have an increasing trend either 
because of improved testing availability or because the 
peak of this pandemic in Pakistan has not been 
reached and the worst is yet to come.
Demographics and Transmission:
As an emerging acute respiratory infectious disease, 
COVID-19 primarily spreads through the respiratory 
tract. Transmission occurs primarily via respiratory 
droplets  within a range of about 1.8 metres (6 ft). 
Indirect contact via contaminated surfaces is another 
possible cause of infection. The virus is inactivated by 
soap, which destabilizes its lipid bilayer. Based on 
current epidemiological investigation, the incubation 
period is 1–14 days, mostly 3–7 days. The pharynx 
reaches peak viral load approximately four days after 
infection and the COVID-19 is contagious during the 
latency period. It is highly transmissible in humans, 
especially in the elderly and people with underlying 
diseases like hypertension, ischemic heart disease and 
diabetes mellitus.  Each infection from the virus is 
expected to result in 1.4 to 3.9 new infections when no 
members of the community are immune and no 
preventive measures are taken. Emerging evidence 
suggests that ambient temperature has no significant 
impact on the transmission of COVID-19; however, 
further research is required on how weather conditions 
influence transmission.6 The median age of patients is 
47–59 years, and 41.9–45.7% of patients are 
females.7
Data from the largest case series in China found that 
87% of confirmed cases were aged 30 to 79 years, 1% 
were aged 9 years or younger, 1% were aged 10 to 19 
years, and 3% were aged 80 years or older. 
Approximately 51% of patients were male and 49% 
were female.8 In the US, older patients (aged ≥65 
years) accounted for 31% of all cases, 45% of 
hospitalizations, 53% of intensive care unit admissions, 
and 80% of deaths, with the highest incidence of 
severe outcomes in patients aged ≥85 years.9 Infection 
in children is reported much less commonly than 
amongst adults. 
Pathophysiology:
SARS CoV2 is an enveloped, positive sense, single 
stranded RNA virus with a diameter of approximately 
60-140 nanometers. The viral envelope consists of a 
lipid bilayer with four structural proteins known as S 
(spike (E (envelope), M (membrane) and N 
(nucleocapsid). Interaction between the spike protein 
and host cell receptor is essential for virulence and 
infectivity.10 Following invasion of the lung epithelium, 
SARS-CoV directly infects T cells and macrophages, 
contributing to lymphopenia with reduced CD4+ and 
CD8+ cell counts and dysregulation of normal adaptive 
immune responses. Excessive production of 
pro-inflammatory cytokines including interleukins (IL-1, 
IL-6, IL-10), and tumor necrosis factor-alpha with 
subsequent downregulation of anti- inflammatory 
cytokines such as interferon gamma  are thought to 
contribute to excessive inflammation and activation of 
pro-apoptotic pathway.11 In some cases, adaptive 
immune responses might become directed against host 
epitopes, resulting in post-infectious autoimmune 
reactions that prolong the inflammatory phase and 
induce tissue destruction even after the virus has been 
cleared.
Mechanisms of Neuronal injury:
Angiotensin-converting enzyme 2 (ACE 2) is the cellular 
receptor for the new SARS-CoV-2 This is present in 
multiple human organs including the brain and glial 
tissue and thus this makes the central nervous system 
a potential target.12 There may be direct infiltration of 
the CNS through the nasal epithelium and entrance 
into the olfactory pathway with the subsequent 
retrograde trans-synaptic spread. Hematogenous 
spread with secondary neurologic manifestations of 
COVID-19 are thought to be the result of widespread 
dysregulation of homeostasis and cytokine production 
with pulmonary, renal, hepatic, and cardiovascular 
injury.13. Besides coronavirus specific antibodies have 
been shown to activate macrophages resulting in their 
migration into the CNS and ultimately cause 
demyelination. Infection with COVID 19 promotes 
atherosclerosis, inflammation and local thrombosis in 
the presence of systemic inflammation the resultant 
elevation in C reactive protein and D dimer increases 
the risk of acute cerebrovascular disease.14 Molecular 
mimicry between specific viral proteins and proteins 
on peripheral nerves (gangliosides) leads to an 
innocent bystander attack against the myelin or axon, 
the most likely mechanism behind peripheral nerve 
injury. There is no current evidence of direct viral 
invasion with inflammation and degeneration of motor 
neurons and peripheral nerves as seen in some other 
viral infections like poliovirus, West Nile, Herpes 
Zoster, or Cytomegalovirus etc.
Neurological symptoms:
Neurological signs and symptoms fall into three main 
categories; central nervous symptoms (CNS), 
peripheral nervous symptoms (PNS) and skeletal 
muscular symptoms.3 These clinical features may be 
the presenting complaints or as more commonly seen 
arise during the more frequently seen respiratory and 
febrile illness. CNS manifestations most commonly 
seen include dizziness, headache, impaired 
consciousness, acute cerebrovascular disease, 
ataxia, and seizures. PNS manifestations included 
taste impairment, smell impairment and nerve pain. 
Skeletal muscular injury manifestations include 
myalgias. In the largest study to date on 214 patients 
from Wuhan, China, overall, 78 patients (36.4%) had 
neurologic manifestations. 126 patients (58.9%) had 
non severe infection and 88 patients (41.1%) had 
severe infection according to their respiratory status. 
Patients with severe infection were more likely to 
develop neurologic manifestations, especially acute 
cerebrovascular disease [5.7%]; conscious 
disturbance [14.8%] and skeletal muscle injury 
[19.3%].3 Another recent report of 99 COVID-19 
patients in Wuhan also described neurological 
complications with confusion (9%) and headache 
(8%) being most commonly seen.15 Most neurologic 
manifestations occur early in the illness (median 
time, 1-2 days). Of 6 patients with acute 
cerebrovascular disease, 2 arrived at the emergency 
department owing to the sudden onset of hemiplegia 
but without any typical symptoms of fever, cough, 
anorexia, and diarrhea of COVID-19.  Their lung 
lesions were found by an emergent lung CT and were 
diagnosed as having COVID-19 by a positive 
SARS-CoV-2 nucleic acid detection in the later 
stage.3 Loss of smell and taste may precede 
respiratory symptoms and suggest early neurological 
involvement. The American Academy of 
Otolaryngology recently proposed that anosmia, 
hyposmia, and dysgeusia should be added to the list 
of COVID-19 screening symptoms and urged 
precautionary isolation for individuals with these 
symptoms, even in the absence of respiratory 
disease.16
Neurological syndromes:
Isolated new cases of COVID 19 with neurological 
syndromes are emerging every day from all around 
the world. Ischemic strokes have been reported in 5% 
of patients with severe COVID -19 infections and in 
1% of non-severe infections due to the COVID 19 
from recent data considering the patients are  in a pro 
thrombotic state.3 There was also one patient with 
spontaneous intra cerebral hemorrhage and cerebral 
venous sinus thrombosis each in the same study.
Encephalopathy and acute hemorrhagic necrotizing 
encephalopathy have recently been reported with 
COVID19 which are rare complications of influenza 
and other viral infections.17 Myopathies, 
rhabdomyolyis, viral myositis, critical illness myopathy 
are all possibilities with COVID19. In recently 
published studies from China myalgia developed in up 
to 44% of hospitalized patients and elevated creatine 
kinase in up to 33%.18 There is no proven direct 
causality with Guillain Barre Syndrome as seen in 
some other viruses like influenza, H1N1, ZIKA, EBV 
etc. however some new case reports exist.19 
Association with demyelination including Multiple 
sclerosis and Acute disseminated encephalomyelitis 
has been reported in the past.20
COVID-19 and Stroke
Acute strokes presenting in endemic areas in 
emergency department may need to be checked for 
COVID-19. The stroke team evaluating for patient 
should divide to conserve personal protective 
equipment and limit the potential for accidental 
exposure. Patients needing tissue plasminogen 
activator (tPA) during the one-hour infusion may be 
monitored every 15 minutes by a single stroke team 
member situated in the patient’s room. In cases of 
mechanical thrombectomy, groin checks can be done 
by team members entering for other reasons every 4 
hours after the initial monitoring in the intervention 
radiology suite.21  Non-contrast head CTs with 
possible or confirmed COVID-19 should be reserved 
for patients with significant change in neurologic 
examination. Repeat imaging in neurologically stable 
patients who have not received IV tPA or mechanical 
thrombectomy should be avoided. Additional studies 
including MRI, Echocardiogram’s and Doppler’s 
should be considered only if likelihood of changing 
management. Even in patients without COVID-19, the 
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effectiveness of routine brain MRI to guide treatment 
selection is uncertain.22
COVID-19 and Seizures 
Metabolic derangements may be common in 
SARS-CoV2 infected patients and these should be 
evaluated for possibly causing seizures. Severely 
affected have compromised renal and hepatic systems 
and appropriate antiseizure medication should be 
carefully selected. Brivaracetam, lacosamide, 
Levetiracetam, Zonisamide is advised with abnormal 
liver tests.23 
COVID19 and Headache
Headache appears to be the most common 
neurological complaint with COVID-19. The putative 
role of ACE2 in the pathophysiology has recently fueled 
concerns regarding the use of non- steroidal 
anti-inflammatory drugs (NSAIDs) such as ibuprofen, 
commonly used for headache. These are known to 
induce up-regulation of ACE2 and, in theory, may 
facilitate infection with COVID-19.24 Sodium valproate 
should be avoided amid to concerns of liver injury.
COVID-19 and GBS
All patients with suspected or diagnosed COVID-19 with 
acute flaccid weakness should be admitted in intensive 
care units. Elective endotracheal intubation should be 
considered when single breath count test < 20, use of 
accessory muscles or paradoxical breathing and neck 
flexion weakness is noted. The generally considered 
CSF analysis for cytological dissociation, maybe 
warranted if it will change therapeutic decision as it 
may be normal in one third to one half in first week of 
symptoms. NCS 1-2 weeks after symptom onset 
should be considered. Intravenous immunoglobulins 
(IVIg) 2g/kg administered over 5 days is the standard of 
care. Plasmapheresis over 5 cycles is an equally 
efficacious alternative. Mild symptoms may not need 
treatment; decision should be weighed against lengthy 
hospital stay.25 The role of high dose IVIg in a recent 
case series published with COVID-19, all of whom were 
successfully treated at the early stage of clinical 
deterioration with the resultant initiation of a 
randomized controlled trial.26 This may lead us to 
rethink the equal efficacy that has been long 
established when treating patients with muscle or nerve 
involvement with plasma exchange versus IVIg. Serial 
PFTs (pulmonary function tests) at least q8h in first 24 
hours. Daily vital sign, urine output, and last bowel 
movement charting should be maintained for 
anticipating autonomic dysfunction. 27
Neuroimaging
Although the full spectrum of neuro-imaging findings in 
COVID 19 is still unknown. The risk of contamination 
remains high. A non-contrast CT Head to exclude acute 
stroke in patients with possible or confirmed COVID 19 
should be reserved for times when actionable 
information is likely to be obtained, or when a 
significant change in the neurological examination is 
seen. A CT angiogram of the head and neck may be 
required in cases of subarachnoid hemorrhage. 
Additional studies including MRI with gadolinium may 
be required in patients with a history of seizures or 
unexplained encephalopathy. In one recently published 
study from Strasbourg, France, between March 3 and 
April 3, 2020 in patients with confirmed COVID 19 with 
encephalopathy. MRI Brain showed leptomeningeal 
enhancement predominately in occipital lobe in eight 
out of 13 patients. Small diffusion abnormalities 
indicating asymptomatic acute ischemic stroke were 
seen in two patients. Bilateral frontotemporal 
hypo-perfusion was noted in all 11 of these patients 
who underwent perfusion imaging.28 Hemorrhagic ring 
enhancing lesions within the bilateral thalami and 
medial temporal lobes on MRI Brain has been 
described in a patient with acute hemorrhagic 
encephalopathy.17 
Cerebrospinal fluid:
A cerebrospinal fluid (CSF) examination may be 
required to exclude possible causes of impaired 
consciousness. All standard tests to exclude CNS 
infections should be done simultaneously despite of 
suspected encephalitis and encephalopathy due to 
COVID-19. Cerebrospinal fluid is usually clear and 
colorless with mild pleocytosis and lymphocytic 
predominance. CSF oligoclonal bands may be present 
with an identical electrophoretic pattern in serum28. 
SARS-CoV-2 nucleocapsid protein genes can be 
detected by using PCR and is recommended in highly 
suspicious cases. In a recent case report with 
meningitis the opening pressure of CSF was increased 
up to 320 mmH2O. The CSF cell count was 12/µ L.  10 
mononuclear and 2 polymorphonuclear cells without 
red blood cells were noted. Although the specific 
SARSCoV-2 RNA was not detected in the 
nasopharyngeal swab of this patient, it was detected in 
CSF.29
Electroencephalogram: 
Electroencephalogram (EEG) may be needed in 
unexplained drowsiness or with uncontrolled seizures. 
Non-convulsive seizures seen in critically ill patients in 
up to 10% .30 24 hour monitoring maybe required in 
appropriate cases, ideally performed with disposable 
EEG leads. Seizures were observed with other types of 
coronavirus infections in up to 6 - 50% of affected 
children.31 The EEG findings although are non-specific 
may show diffuse or bifrontal slowing consistent with 
encephalopathy.28
Nerve conduction studies and electromyography:
Nerve conduction studies (NCS) and 
electromyography (EMG) may be necessary with 
patient acute flaccid paralysis or myositis. Reports of 
GBS in association with COVID-19 have recently been 
seen.32 An over-emphasis on the fact that NCS and 
EMG are within normal limits in the first 1-2 weeks in 
diseases of the muscle and nerves cannot be made. 
Unnecessary procedures should be avoided as the 
machines may serve as fomites.
Laboratory evaluation:
Laboratory findings in patients with COVID -19 include 
high white blood cell counts, lower lymphocyte count, 
and increased C-reactive protein. Severe infection 
has corresponding higher D-dimer levels, increased 
lactate dehydrogenase, alanine aminotransferase, 
and aspartate aminotransferase levels, with elevated 
blood urea nitrogen, creatinine levels and creatine 
kinase (CPK) levels.
Management:
Patient with neurological manifestations and COVID 
19 may require hospitalization with intensive care 
monitoring. Minimal exposure of healthcare and still 
providing the best possible care to patients should be 
the aim. 
Long term neurological complications of SARS 
and other corona viruses:
Delayed neurologic sequelae after 2 weeks of 
respiratory issues have been described following both 
SARS-CoV-1 and MERS-CoV infection, such as 
peripheral neuropathy, myopathy, Bickerstaff 
brainstem encephalitis, and GBS.33,34
Although there is limited data for COVID-19-related 
psychiatric symptoms currently, survivors of 
SARS-CoV were clinically diagnosed with 
post-traumatic stress disorder (54.5%), depression 
(39%), pain disorder (36.4%), panic disorder 
(32.5%), and obsessive compulsive disorder (15.6%) 
at 31 to 50 months post-infection, a dramatic 
increase from their pre-infection prevalence of any 
psychiatric diagnoses of 3%.35 Parkinsonism is a late 
feature of encephalitis lethargica, first described 
following the influenza pandemic of 1918.36 While 
features of Parkinsonism have not been described in 
association with CoV outbreaks, anti-CoV antibodies 
have been identified in CSF of individuals with 
Parkinson’s disease. It is plausible that this could 
contribute to a  delayed neurodegenerative process 
but this  remains to be seen in COVID-19.
Prognosis: 
Neurological manifestations may have a variable 
prognosis. Patients with milder disease or isolated 
symptoms such as anosmia, ageusia, isolated 
headaches or myalgias suggest a relatively better 
outcome. However, those with more severe systemic 
disease and extensive neurological involvement like 
strokes, encephalitis or Guillain Barre syndrome may 
have a graver outcome.
Future directions for research:
Understanding the full spectrum of the neurotropic 
effects of COVID 19 is still in its maiden stages. 
Neurological manifestations until now have depicted 
the entire neuroaxis is prone to disease. 
Pharmaceutical research needs to change directions 
to expedite the development of a possible vaccine 
and also accelerate in the quest for newer antiviral 
agents. More extensive neurological workup or 
autopsies and isolation of SARS CoV 2 from neural 
tissue may help in aiding us to understand the 
mechanism of COVID 19 better. Management 
protocols may need to be revised as we learn more 
about neurological complications every day.
CONCLUSION:
A multi-disciplinary approach is required to control 
this massive challenge faced by humanity. Health 
care providers should keep a close watch for isolated 
neurological symptoms at presentation when 
evaluating patients for COVID 19 to assure both 
appropriate management and control of disease. A 
directed neurological examination limiting exposure of 
medical personnel to potentially infected patients is 
mandatory. Appropriate constrained investigations 
should be considered only if there is a likelihood of 
changing management. Research for new anti-viral 
drugs and the development of a possible vaccine is 
cardinal for the management. Tele neurology 
consultations whenever possible is the need of the 
hour. Outcomes of COVID 19 patients with severe 
illness and neurological complications remains grave
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